| Literature DB >> 30991026 |
Laura Hinze1, Maren Pfirrmann2, Salmaan Karim2, James Degar2, Connor McGuckin2, Divya Vinjamur2, Joshua Sacher3, Kristen E Stevenson4, Donna S Neuberg4, Esteban Orellana5, Martin Stanulla6, Richard I Gregory5, Daniel E Bauer7, Florence F Wagner3, Kimberly Stegmaier8, Alejandro Gutierrez9.
Abstract
Resistance to asparaginase, an antileukemic enzyme that depletes asparagine, is a common clinical problem. Using a genome-wide CRISPR/Cas9 screen, we found a synthetic lethal interaction between Wnt pathway activation and asparaginase in acute leukemias resistant to this enzyme. Wnt pathway activation induced asparaginase sensitivity in distinct treatment-resistant subtypes of acute leukemia, but not in normal hematopoietic progenitors. Sensitization to asparaginase was mediated by Wnt-dependent stabilization of proteins (Wnt/STOP), which inhibits glycogen synthase kinase 3 (GSK3)-dependent protein ubiquitination and proteasomal degradation, a catabolic source of asparagine. Inhibiting the alpha isoform of GSK3 phenocopied this effect, and pharmacologic GSK3α inhibition profoundly sensitized drug-resistant leukemias to asparaginase. Our findings provide a molecular rationale for activation of Wnt/STOP signaling to improve the therapeutic index of asparaginase.Entities:
Keywords: FBXW7; GSK3; Wnt signaling; acute leukemia; asparaginase; asparagine; drug resistance; proteasomal degradation; protein ubiquitination; synthetic lethality
Mesh:
Substances:
Year: 2019 PMID: 30991026 PMCID: PMC6541931 DOI: 10.1016/j.ccell.2019.03.004
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743